Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Veloxis Pharmaceuticals A/S    VELO   DK0060048148

VELOXIS PHARMACEUTICALS A/S (VELO)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
02/15/2018 02/16/2018 02/19/2018 02/20/2018 02/21/2018 Date
0.898(c) 0.9(c) 0.895(c) 0.88(c) 0.867 Last
3 834 643 468 824 193 064 386 204 358 877 Volume
+5.65% +0.22% -0.56% -1.68% -1.48% Change
More quotes
Financials ( DKK)
Sales 2017 18,0 M
EBIT 2017 -17,0 M
Net income 2017 -17,0 M
Debt 2017 32,0 M
Yield 2017 -
Sales 2018 25,0 M
EBIT 2018 210 M
Net income 2018 210 M
Finance 2018 181 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 8,95
EV / Sales2017 86,9x
EV / Sales2018 54,0x
Capitalization 1 532 M
More Financials
Company
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients.The company is focused on the direct commercialization of Envarsus XR in the US,... 
More about the company
Latest news on VELOXIS PHARMACEUTICALS A/
02/16VELOXIS PHARMACEUTICALS A/S : Secures USD 60M in Debt Financing
AQ
02/14VELOXIS PHARMACEUTICALS A/S : Secures USD 60M in Debt Financing
AQ
2017VELOXIS PHARMACEUTICALS A/S : Announces Financial Calendar for 2018
AQ
2017VELOXIS PHARMACEUTICALS A/S : Grants Warrants under Existing Warrant Program
AQ
2017VELOXIS PHARMACEUTICALS A/S : Grants Warrants Under Existing Warrant Program
AQ
2017VELOXIS PHARMACEUTICALS A/S : Increases Share Capital in Connection with Exercis..
AQ
2017VELOXIS PHARMACEUTICALS A/S : Increases Share Capital in Connection with Exercis..
AQ
2017VELOXIS PHARMACEUTICALS A/S : Announces Financial Results for the First Nine Mon..
AQ
2017VELOXIS PHARMACEUTICALS A/S : quaterly earnings release
2017VELOXIS PHARMACEUTICALS A/S : AS Grants Warrants Under Existing Warrant Program
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
2017Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months.. 
2017Veloxis Pharmaceuticals A S ADR reports Q3 results  
2017Veloxis Pharmaceuticals : Announces Financial Results for the First Nine Mont.. 
2017Loss of diver Michael Heffernan during Mayo cave rescue 20 years ago also rec..
2
2017Veloxis Pharmaceuticals A/S: Veloxis Announces the Total Number of Shares and.. 
More tweets
Qtime:28
News from SeekingAlpha
2016Veloxis Pharmaceuticals reports 1H16 results 
2015Veloxis Pharma's once-daily Envarsus an Orphan Drug for prevention of organ r.. 
2015PREMARKET BIOTECH DIGEST : Pfizer In China, Anavex Alzheimer's Focus 
2015FDA clears Veloxis Pharma's extended-release Envarus for the prevention of re.. 
Chart VELOXIS PHARMACEUTICALS A/
Duration : Period :
Veloxis Pharmaceuticals A/ Technical Analysis Chart | VELO | DK0060048148 | 4-Traders
Technical analysis trends VELOXIS PHARMACEUTICALS A/
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus
Number of Analysts 2
Average target price 0,86  DKK
Spread / Average Target -3,9%
EPS Revisions
Managers
NameTitle
Craig A. Collard President & Chief Executive Officer
Michael Thomas Heffernan Chairman
Ulf Meier-Kriesche Chief Scientific Officer
Anders Götzsche Independent Director
Mette Kirstine Agger Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
VELOXIS PHARMACEUTICALS A/S4.42%254
CELLTRION, INC.--.--%34 924
IQVIA HOLDINGS INC6.93%21 157
LONZA GROUP-7.82%19 259
INCYTE CORPORATION-6.91%18 046
NEKTAR THERAPEUTICS40.66%13 138